Scilex Holding Company provided sales guidance for the fiscal year ended December 31, 2023. For the period, the company expects total product net sales were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.115 USD | +2.29% | +2.75% | -45.10% |
Jun. 06 | Sector Update: Health Care Stocks Higher in Late Afternoon Trading | MT |
Jun. 06 | Scilex Shares Advance after FDA Approves Production of Gout Medication | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.10% | 132M | |
+19.29% | 80.5B | |
+15.08% | 9.15B | |
-18.33% | 4.9B | |
+43.39% | 4.49B | |
+13.95% | 4.44B | |
+10.89% | 2.19B | |
-28.40% | 2.13B | |
+15.93% | 2.1B | |
-43.17% | 1.78B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023